Several ACA Preventive Services “Up for Grabs” Following Federal Ruling
March 31st 2023The ruling does not completely get rid of all preventive services coverage under the Affordable Care Act; it only applies to updates or new recommendations made by the US Preventative Services Task Force since March 2010.
Read More
Dr Samyukta Mullangi Explains How Thyme Care Integrates SDOH When Personalizing Care Navigation
March 31st 2023Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, spoke on how her organization’s tech platform incorporates social determinants of health (SDOH) in care navigation to ensure high quality care and treatment.
Watch
Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma
March 30th 2023Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.
Read More
Prurigo Nodularis Improves Following Treatment With Dupilumab
March 30th 2023Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.
Read More
Bridging the Gap in Health Care Inequities: Considerations in Treatment Selection, Part 1
March 30th 2023In part 1 of this 2-part series on health equity in the treatment of psoriasis, Ryan Haumschild, PharmD, and Bryan Buckley, DrPH, discuss how providers can address disparities in care, specifically with race, cultural, and ethnic backgrounds in mind.
Listen
Immunotherapy for NSCLC Safe in Elderly Patients, but More Research Needed
March 30th 2023A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).
Read More
Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
March 29th 2023The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
Read More
CVD Outcomes Investigation Highlights Need for More, Better Data on SDOH
March 29th 2023This study of the public health landscape in New York City investigated the interplay between social determinants of health (SDOH), chronic health conditions, and inequities in social factors, with a focus on cardiovascular disease (CVD).
Read More